Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

or new therapies that could offer patients less frequent dosing regimens and better tolerability."

The randomized, double-blind, placebo-controlled, in-clinic trial used a cross-over design to evaluate the efficacy, safety and tolerability of three doses of NGX267. A total of 26 patients with xerostomia associated with primary or secondary Sjogren's syndrome were enrolled at three sites in the United States. In four distinct treatment periods, each patient was randomized to receive a single dose of 10 mg, 15 mg and 20 mg of NGX267 and placebo. Patients remained in the clinic and serial efficacy assessments were taken at scheduled time points through 24 hours post dosing. For the primary endpoint, whole mouth salivary flow was collected by passive drainage into pre-weighed containers. Secondary endpoints included maximum change in salivary flow rate compared to predose and an 8-item salivary flow questionnaire completed by the patient that assessed the impact of dry mouth across various dimensions of patient functioning.

The 10 mg, 15 mg and 20 mg doses of NGX267 produced statistically significant increases in salivary flow compared to placebo across a number of time points, including the mean salivary flow production over the 24 hour post-dosing period (p=0.025, 0.001, and 0.001, respectively). In addition, the maximum change in salivary flow was statistically significant compared to placebo for each of the three doses of NGX267. Results of the 8-item patient self-assessment correlated with the quantitative results of salivary production. At the 15 mg and 20 mg doses, statistically significant differences compared to placebo were demonstrated in a variety of domains including items that rated improvement in speaking and swallowing, dryness of mouth and level of thirst.

Safety was monitored throughout the evaluation period and NGX267 was shown to be safe and well-tolerated. All patients completed all tr
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... LOS ANGELES , Sept. 1, 2015 /PRNewswire/ ... biopharmaceutical research and development company specializing in oncology, ... Chairman and Chief Executive Officer, and David ... Investor Relations, will present a corporate overview at ... spotlight the biotechnology and healthcare industries: the FBR ...
(Date:9/1/2015)... , Sept. 1, 2015 Pressure ... a leader in the development and sale of ... solutions to the worldwide life sciences industry, today ... that suggest the Company,s PCT Platform could play ... personalized/precision medicine.  This role is based on PCT,s ...
(Date:9/1/2015)... -- BerGenBio AS ("BerGenBio" or the "Company"), ... appointed Hilde Furberg and Dr Stener ... Directors, effective immediately. Hilde Furberg ... biotech and is currently Senior Vice President Rare Diseases ... was Vice President and General Manager of Nordic Benelux ...
Breaking Medicine Technology:CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5BerGenBio Appoints Non-Executive Directors 2
... Oct. 24, 2011 PhotoMedex , Inc. (NASDAQ: ... including the XTRAC® excimer laser ( www.XTRACLaser.com ), is offering ... XTRAC psoriasis treatments for children, an underserved population of ... presented in recognition of World Psoriasis Day ...
... 24, 2011 HealthWarehouse.com, Inc. (OTC: HEWA), a ... it will begin providing prescription medications for WhiteGlove ... "We,re excited to have a national partner ... areas," said Robert Fabbio, co-founder and chief executive ...
Cached Medicine Technology:PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 2PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 3PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 4WhiteGlove Health Selects HealthWarehouse.com to Provide Prescription Medications to its Members Nationwide 2
(Date:9/1/2015)... Meadows, Ill. (PRWEB) , ... September 01, 2015 ... ... procedures done by members of the American Society for Dermatologic Surgery, according to ... , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures – which reflects ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia entrepreneur Marcella Ellis, ... strongly maintaining her firm’s success in the hair care and distribution industry through ... tour, Ellis will be providing “Look and learn” live demonstrations, as well as ...
(Date:9/1/2015)... , ... September 01, 2015 , ... The Jerry Segal ... The ACE Club and Green Valley Country Club in Lafayette Hill, PA. Over the ... more than $13.5 million for programs and services designed to support patients and their ...
(Date:9/1/2015)... ... September 01, 2015 , ... e-Spirit ... version 5.2 of the FirstSpirit Content Management System with new capabilities and enhancements ... version of FirstSpirit, companies will be well on their way to achieving digital ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... The ... and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection ... same mission – to raise awareness of the FSH Society and further FSHD research. ...
Breaking Medicine News(10 mins):Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3
... May 25, 2011 The American Society for Radiation Oncology ... Bernard Cummings, MB, ChB, FASTRO, as the Society,s 2011 Gold ... this honor at the Awards Ceremony held during ASTRO,s 53rd ... Fla. The Gold Medal is the Society,s highest honor. It ...
... by Trinity College Dublin that aims to ... selected for grant funding of 6 million by the ... NILVAD*, comprising 18 European universities, hospitals and pharmaceutical companies, ... treatment of Alzheimer,s disease (AD). Trinity College ...
... 20, most people have reached skeletal maturity and do not grow ... in the body also stopped by age 20. But a ... Chapel Hill has found evidence that, even though you,re not getting ... advance in age from 20 years to 79 years. "I ...
... National Institute of Standards and Technology (NIST) has released ... manufacturers evaluate the composition of their products and assure ... the human health effects of this popular beverage and ... prepared as part of an ongoing collaboration with the ...
... , TUESDAY, May 24 (HealthDay News) -- Long known as ... heart failure, a new study suggests. Research tracking more ... found that those whose diets included more baked and broiled ... -- had a 30 percent lower risk of heart failure ...
... care doctors have long been on the front lines of ... in 10 office visits and primary care doctors prescribe more ... University of Michigan Health System have developed a new tool ... which a patient,s depression has improved. The issue, the ...
Cached Medicine News:Health News:Ang, Cummings to receive ASTRO Gold Medal 2Health News:Clinical trials for new Alzheimer's disease treatment to be awarded European Commission €6m funding 2Health News:Pelvic widening continues throughout a person's lifetime, UNC study 2Health News:Care for a spot of (green) tea? New NIST reference materials for popular diet supplement 2Health News:Cooked Right, Fish Can Help a Woman's Heart 2Health News:Cooked Right, Fish Can Help a Woman's Heart 3Health News:New tool aims to improve measurement of primary care depression outcomes 2
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
Medicine Products: